Skip to content

Use of Lumella-glycosylated Fibronectin for Diagnosis of Preeclampsia

Lumella is a Point of Care Blood Test Used Together With Other Blood Tests to Assess the Risk of Preeclampsia in Pregnancy in 10 Minutes. Measurements of the Biomarker.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06085001
Acronym
Lumella
Enrollment
50
Registered
2023-10-16
Start date
2023-11-10
Completion date
2024-08-30
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Preeclampsia, Pregnancy Related

Keywords

Preeclampsia, PET

Brief summary

women with symptoms of preeclampsia from antenatal clinic or triage will be offered Lumella test along with traditional blood tests. If Lumella test is positive which will be compared with the traditional blood test results. Once 50 positive cases have been analysed the study results will be submitted to NICE.

Detailed description

Pre-eclampsia is a potentially serious condition that affects pregnant women. It is usually diagnosed during routine antenatal appointments. This is based on blood pressure measurements and results of urine protein tests that are recommended at each routine antenatal visit to screen for the condition. The Triage PlGF test and the Elecsys immunoassay sFlt-1/PlGF ratio is also recommended to help rule out the condition in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks of pregnancy plus 6 days. If diagnosed with pre-eclampsia, women are usually referred to a specialist in hospital for further tests and more frequent monitoring. Depending on the severity of the condition, some women may be monitored as outpatients while others may need admission to hospital for closer monitoring or to have the condition managed in a critical care setting. The Lumella test is based on the novel biomarker GlyFn. The company states that compared with other currently used biomarkers (such as soluble fms-like tyrosine kinase-1 \[sfIT-1\] and placental growth factor \[PlGF\] or PlGF alone), GlyFn is etiological to pre-eclampsia and maintains a linear progression throughout pregnancy. The company also claims that the test offers improved sensitivity and specificity over standard care tests. This would lead to a reduction in false positives and false negatives. The Lumella test requires a finger prick blood sample (5 microlitres). Other pre-eclampsia tests currently used in the NHS need a phlebotomy blood sample, which can be difficult to collect in some people. The test can also be transported and stored at room temperature. Other tests for pre-eclampsia need to be refrigerated and brought to room temperature before the test can be done. The Lumella test may improve patient experience and allow a more rapid turnaround time for results. The company states that Lumella is currently the only test that can be done within 10 minutes at room temperature.

Interventions

DIAGNOSTIC_TESTLumella finger prick blood test

Finger prick blood test

Sponsors

Croydon University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* If they can speak English * Can give informed consent * Has symptoms of Preeclampsia

Exclusion criteria

* Can't speak English * Does not want to participate

Design outcomes

Primary

MeasureTime frameDescription
can we use a bedside test -glycosylated fibronectin for the early diagnosis of pre-eclampsia6 monthsDoes the test work?

Secondary

MeasureTime frameDescription
Is glycosylated fibronectin better than placental growth factor or traditional blood tests6 monthsIs the test better than PLGF/traditional blood tests

Countries

United Kingdom

Contacts

Primary ContactMichael Chang
michael.chang@nhs.net+442084013610
Backup ContactDaniel Annan
daniel.annan@nhs.net+442084013000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026